Can-Fite BioPharma (CANF): Rentabilitas dodolan miturut bathi resik

Logo perusahaan publik Can-Fite BioPharma Ltd (CANF)

Monthly sales margin dynamics demonstrate the impact of the cancer and psoriasis drug ecosystem, where the -2358.70 metric reflects current trends. Can-Fite BioPharma (CANF) management aims to commercialize developments following the completion of final trial stages. Meanwhile, the diversification of centers across Europe and the US minimizes regional risks, ensuring the stability of the Israeli biotech firm under current conditions.

CANF: Tingkat bathi resik canfite.com 04.07.2022 - 19.11.2026

Can-Fite BioPharma, Ltd. (CANF) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis komprehensif perusahaan:Can-Fite BioPharma
Barang unggulan Can-Fite BioPharma Ltd

The efficiency of Can-Fite BioPharma (CANF) in developing drugs against cancer and psoriasis is reflected in its ability to convert revenue into net income. This metric is calculated as the ratio of net profit to total sales, measuring the ultimate profitability of the business. The current time series for net margin recorded a value of -2358.70. The dynamics of this indicator allow for an assessment of operational resilience when entering new markets. Steady growth of this indicator confirms the strengthening of the company's capital.